基线转移灶生长速率是晚期BRAF V600突变黑色素瘤接受靶向治疗患者的独立预后标志物
本研究回顾性分析7个皮肤肿瘤中心242例接受靶向治疗的可测量晚期黑色素瘤患者,基线转移灶生长速率(MGR)>3.9 mm/月者总生存和无进展生存均显著受损,且该预后影响独立于LDH、脑肝转移、肿瘤负荷和治疗线数。
要点
- 基线MGR>3.9 mm/月者中位OS为11.4个月 vs 35.5个月,中位PFS为4.8个月 vs 9.2个月。
- MGR升高的预后影响独立于LDH、脑转移、肝转移、肿瘤负荷和治疗线数。
- MGR的预后意义在LDH正常患者中最高。
核心结论
- 基线MGR是接受靶向治疗的黑色素瘤患者OS和PFS的重要独立预后标志物,易于在临床常规中实施并有助于预后分层。
研究设计与样本
- 回顾性分析7个皮肤肿瘤中心242例至少有一个可测量靶病灶并接受靶向治疗的患者临床记录,基线MGR通过测量基线及一个更早时间点的最大靶病灶确定。
主要发现
- MGR>3.9 mm/月患者中位OS为11.4个月 vs 35.5个月(P<0.0001),中位PFS为4.8个月 vs 9.2个月(P<0.0001)。
- 多因素分析显示MGR升高的预后影响独立于LDH、脑转移、肝转移、肿瘤负荷和治疗线数。
- MGR升高的预后意义在LDH正常患者中最高。
关键数值与推荐
- MGR阈值3.9 mm/月,高于此值者OS和PFS显著受损。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted therapy (TT) of BRAF V600 mutated unresectable melanoma with inhibitors of the MAPK pathway achieves response rates of up to 76%, but most patients develop secondary resistance. Albeit TT is strikingly efficacious during the first days of treatment, even in advanced cases, long-term survival is highly unlikely, especially in patients with unfavorable baseline characteristics like elevated lactate dehydrogenase (LDH). In patients treated with anti-PD-1 immune checkpoint inhibitors, elevated baseline metastatic growth rate (MGR) was the most important prognostic factor. Here, we aimed at investigating the prognostic impact of MGR in patients with unresectable melanoma receiving TT. METHODS: Clinical records of 242 patients with at least one measurable target lesion (TL) receiving TT at seven skin cancer centers were reviewed. Baseline MGR was determined measuring the largest TL at baseline and at one earlier timepoint. RESULTS: Overall survival (OS) and progression-free survival (PFS) were significantly impaired in patients with an MGR > 3.9 mm/month (median OS: 11.4 vs. 35.5 months, P < 0.0001; median PFS: 4.8 vs. 9.2 months, P < 0.0001). Multivariable analysis of OS and PFS revealed that the prognostic impact of elevated MGR was independent of LDH, presence of brain and liver metastases, tumor burden, and line of treatment. The prognostic significance of elevated MGR was highest in patients with normal LDH. CONCLUSIONS: Baseline MGR is an important independent prognostic marker for OS and PFS in melanoma patients treated with TT. Its implementation in clinical routine is easy and could facilitate the prognostic stratification.
引用
- Wagner NB, Lenders MM, Kühl K, et al. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. Eur J Cancer. 2023. PMID: 38039778. doi:10.1016/j.ejca.2023.113425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。